{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:05:19Z","timestamp":1776179119434,"version":"3.50.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>This report presents two cases of chemical pneumonitis caused by the exposure of sodium ibandronate powder, a bisphosphonate used for treating osteoporosis. They are both pharmaceutical workers, and they inhaled the powder after an accidental spill in the lab. They developed similar symptoms, but different imaging features, only one showed fibrotic changes. After the blood test and bronchoscopy examination, they both diagnosed as chemical pneumonitis. Their symptoms improved after treatment with glucocorticoids. Their lung lesions resolved completely after continued treatment. The findings suggest that the importance of appropriate safety measures in environments where pharmaceutical powders may be handled, such as in the pharmaceutical industry. Chemical pneumonitis from inhaled sodium ibandronate can have varying CT appearances and may benefit from glucocorticoids therapy.<\/jats:p>","DOI":"10.3389\/fpubh.2025.1523207","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:55:46Z","timestamp":1740725746000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case series: Chemical pneumonitis caused by exposure of sodium ibandronate powder"],"prefix":"10.3389","volume":"13","author":[{"given":"Ting","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.ejrad.2014.04.024","article-title":"Acute and subacute chemical-induced lung injuries: HRCT findings","volume":"83","author":"Akira","year":"2014","journal-title":"Eur J Radiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1592\/phco.26.5.655","article-title":"Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy","volume":"26","author":"Guay","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00003495-199957010-00011","article-title":"Ibandronate","volume":"57","author":"Dooley","year":"1999","journal-title":"Drugs"},{"key":"ref5","year":"2024"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1378\/chest.94.1.208","article-title":"Chemical pneumonitis due to exposure to bromine compounds","volume":"94","author":"Kraut","year":"1988","journal-title":"Chest"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijerph19137954","article-title":"Chemical pneumonitis caused by the inhalation of zinc oxide fumes in an arc welder","volume":"19","author":"Cha","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1164\/rccm.201904-0734IM","article-title":"Chemical pneumonitis caused by inhalation of white phosphorus fumes","volume":"201","author":"Okazaki","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcrc.2014.07.011","article-title":"Aspiration pneumonia: a review of modern trends","volume":"30","author":"DiBardino","year":"2015","journal-title":"J Crit Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.tox.2012.06.020","article-title":"Corticosteroid treatment inhibits airway hyperresponsiveness and lung injury in a murine model of chemical-induced airway inflammation","volume":"301","author":"Wigenstam","year":"2012","journal-title":"Toxicology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.taap.2013.06.009","article-title":"Inhibition of chlorine-induced pulmonary inflammation and edema by mometasone and budesonide","volume":"272","author":"Chen","year":"2013","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1523207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:55:48Z","timestamp":1740725748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1523207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":11,"alternative-id":["10.3389\/fpubh.2025.1523207"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1523207","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"1523207"}}